Is Screening for Ovarian Cancer Cost-Effective?
A reduction in the mortality rate
The MMS was able to offer a reduction of fifteen percent in mortality - a very significant impact on the lives of those at risk. The incremental cost-effectiveness ratio was seen to be between $106,187 and $155,256.
The authors of the study noted, "these results are limited by uncertainty around the effect of screening on ovarian cancer mortality beyond the 11 years of [the] United Kingdom Collaborative Trial of Ovarian Cancer Screening."
